Toronto, ON – The MaRS Discovery District (MaRS) and the Canadian Stem Cell Network (SCN) are partnering in a translational development company called Aggregate Therapeutics.
They plan to expand Aggregate’s work in regenerative medicine, build commercialization capacity in the field of stem cells and regenerative medicine, and facilitate the private financing of spin-off companies from Aggregate.
Aggregate develops products and therapies in the high growth area of regenerative medicine, which includes stem cell therapies, tissue engineering, and biomaterials. It holds the exclusive rights to work to commercialize promising stem cell technologies of 37 leading Canadian scientists at 16 major university and hospital research institutes.
MaRS says this radically new commercialization model allows investors to quickly identify the most innovative convergent technologies by offering them a central point to access early intellectual property.
MaRS takes over immediate ongoing management and governance responsibilities for Aggregate. MaRS will also provide SCN academic members with commercialization services, including market research, translational development, and intellectual property guidance.